RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI), and Retina Consultants of America (RCA), the largest retina care provider in the U.S. with more than 1.7M annual patient visits and over 200 locations in the U.S , have announced a strategic partnership to develop the most extensive and AI-insight driven Real World Evidence (RWE) U.S.-based database in Ophthalmology.
This groundbreaking partnership will leverage RetinAI's innovative digital health technologies and RCA's robust network of clinics to analyze real-world health clinical and imaging data. The result will be a comprehensive resource that provides valuable insights into health outcomes, medication adherence, and the effectiveness of various treatment protocols. By using RCA’s quality-driven datasets and best-in-practice imaging standards for ophthalmic care and RetinAI’s Discovery® platform to aggregate, organize and analyze multimodal data at scale including the company’s certified and advanced research AI models for biomarker analysis and predictive disease analytics, the database will combine the best in clinical and imaging data with exceptionally detailed insights.
With the growing demand for real-world data from the industry, this partnership is poised to make a significant impact on data-driven decisions. The RWE database will offer healthcare stakeholders an unparalleled opportunity to gain insights into drug efficacy, improve drug development processes, and enhance patient care.
The companies will invest in efforts to provide licensed access to the RWE data in Q4’2023 to stakeholders interested in analysis, research and clinical study design for optimizing patient care. RCA and RetinAI will generate RWE in retinal diseases such as Age-related Macular Degeneration (AMD) - including intermediate AMD (iAMD), Geographic Atrophy (GA) and neovascular AMD (nAMD) - and Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and expand to areas of Cardiovascular and Neurodegenerative Diseases where retinal imaging plays a role in identifying disease.
Read the full press release from RetinAI.